世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

CDターゲット二重特異性抗体 - 世界市場シェアとランキング、全体売上高と需要予測 2024-2030


CD Targeted Bispecific Antibody - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

CDターゲット二重特異性抗体の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に%のCAGRで2030年までに100万米ドルの再調整された規模になると予測されています。 CDタ... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2024年3月22日 US$3,950
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

CDターゲット二重特異性抗体の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に%のCAGRで2030年までに100万米ドルの再調整された規模になると予測されています。
CDターゲット二重特異性抗体の北米市場は、2023年に百万米ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに百万米ドルに達すると予測されています。
CDターゲット二重特異性抗体のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに100万ドルに達するでしょう。
CDターゲット二重特異性抗体のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに100万ドルに達するでしょう。
CD標的二重特異性抗体の世界の主要企業には、Aptevo Therapeutics、Affimed Gmbh、Sutro Biopharma、Igm Biosciences、Xencor、Amgen、Genentech Usa、Astella Pharma、Ben Kang Biopharmaceutical (Shenzhen)などがある。2023年には、世界の大手5社が売上高で約 %のシェアを占めている。

レポートの範囲
本レポートは、CD標的二重特異性抗体の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当て、包括的なプレゼンテーションを提供することを目的としています。
CDターゲット二重特異性抗体の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量的、定性的分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場での地位を分析し、CD標的二重特異性抗体に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
アプテボ・セラピューティクス
アフィメド
サトロ・バイオファーマ
イグム・バイオサイエンシズ
ゼンコール
アムジェン
ジェネンテックUSA
アステラファーマ
ベンカンバイオファーマ(深圳)
メルス
リジェネロン製薬
タイプ別セグメント
CD3
CD20
CD40
その他
用途別セグメント
バイオテクノロジー
ラボ
その他
地域別
北米
アメリカ
カナダ
欧州
ドイツ
フランス
英国
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦

各章の概要
第1章:報告書のスコープ、世界の総市場規模を紹介。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:CDターゲット二重特異性抗体メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:各市場セグメントの市場規模と発展の可能性を網羅し、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つけるのに役立つ、タイプ別の様々な市場セグメントの分析を提供します。
第4章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる川下市場のブルーオーシャン市場を見つけるのを助ける。
第5章:CDターゲット二重特異性抗体の地域レベルでの収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場スペース、市場規模を紹介しています。
第6章 CDターゲット二重特異性抗体の国別収益。各国・地域のタイプ別、用途別のシグメイトデータを掲載しています。
第7章:主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 CD Targeted Bispecific Antibody Product Introduction
1.2 Global CD Targeted Bispecific Antibody Market Size Forecast
1.3 CD Targeted Bispecific Antibody Market Trends & Drivers
1.3.1 CD Targeted Bispecific Antibody Industry Trends
1.3.2 CD Targeted Bispecific Antibody Market Drivers & Opportunity
1.3.3 CD Targeted Bispecific Antibody Market Challenges
1.3.4 CD Targeted Bispecific Antibody Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CD Targeted Bispecific Antibody Players Revenue Ranking (2023)
2.2 Global CD Targeted Bispecific Antibody Revenue by Company (2019-2024)
2.3 Key Companies CD Targeted Bispecific Antibody Manufacturing Base Distribution and Headquarters
2.4 Key Companies CD Targeted Bispecific Antibody Product Offered
2.5 Key Companies Time to Begin Mass Production of CD Targeted Bispecific Antibody
2.6 CD Targeted Bispecific Antibody Market Competitive Analysis
2.6.1 CD Targeted Bispecific Antibody Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by CD Targeted Bispecific Antibody Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD Targeted Bispecific Antibody as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CD3
3.1.2 CD20
3.1.3 CD40
3.1.4 Others
3.2 Global CD Targeted Bispecific Antibody Sales Value by Type
3.2.1 Global CD Targeted Bispecific Antibody Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CD Targeted Bispecific Antibody Sales Value, by Type (2019-2030)
3.2.3 Global CD Targeted Bispecific Antibody Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Biotechnology
4.1.2 Laboratory
4.1.3 Others
4.2 Global CD Targeted Bispecific Antibody Sales Value by Application
4.2.1 Global CD Targeted Bispecific Antibody Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CD Targeted Bispecific Antibody Sales Value, by Application (2019-2030)
4.2.3 Global CD Targeted Bispecific Antibody Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global CD Targeted Bispecific Antibody Sales Value by Region
5.1.1 Global CD Targeted Bispecific Antibody Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CD Targeted Bispecific Antibody Sales Value by Region (2019-2024)
5.1.3 Global CD Targeted Bispecific Antibody Sales Value by Region (2025-2030)
5.1.4 Global CD Targeted Bispecific Antibody Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.2.2 North America CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.3.2 Europe CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.4.2 Asia Pacific CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.5.2 South America CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.6.2 Middle East & Africa CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CD Targeted Bispecific Antibody Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CD Targeted Bispecific Antibody Sales Value
6.3 United States
6.3.1 United States CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.3.2 United States CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.4.2 Europe CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.5.2 China CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.5.3 China CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.6.2 Japan CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.7.2 South Korea CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.8.2 Southeast Asia CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.9.2 India CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.9.3 India CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Aptevo Therapeutics
7.1.1 Aptevo Therapeutics Profile
7.1.2 Aptevo Therapeutics Main Business
7.1.3 Aptevo Therapeutics CD Targeted Bispecific Antibody Products, Services and Solutions
7.1.4 Aptevo Therapeutics CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.1.5 Aptevo Therapeutics Recent Developments
7.2 Affimed Gmbh
7.2.1 Affimed Gmbh Profile
7.2.2 Affimed Gmbh Main Business
7.2.3 Affimed Gmbh CD Targeted Bispecific Antibody Products, Services and Solutions
7.2.4 Affimed Gmbh CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.2.5 Affimed Gmbh Recent Developments
7.3 Sutro Biopharma
7.3.1 Sutro Biopharma Profile
7.3.2 Sutro Biopharma Main Business
7.3.3 Sutro Biopharma CD Targeted Bispecific Antibody Products, Services and Solutions
7.3.4 Sutro Biopharma CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.3.5 Igm Biosciences Recent Developments
7.4 Igm Biosciences
7.4.1 Igm Biosciences Profile
7.4.2 Igm Biosciences Main Business
7.4.3 Igm Biosciences CD Targeted Bispecific Antibody Products, Services and Solutions
7.4.4 Igm Biosciences CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.4.5 Igm Biosciences Recent Developments
7.5 Xencor
7.5.1 Xencor Profile
7.5.2 Xencor Main Business
7.5.3 Xencor CD Targeted Bispecific Antibody Products, Services and Solutions
7.5.4 Xencor CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.5.5 Xencor Recent Developments
7.6 Amgen
7.6.1 Amgen Profile
7.6.2 Amgen Main Business
7.6.3 Amgen CD Targeted Bispecific Antibody Products, Services and Solutions
7.6.4 Amgen CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.6.5 Amgen Recent Developments
7.7 Genentech Usa
7.7.1 Genentech Usa Profile
7.7.2 Genentech Usa Main Business
7.7.3 Genentech Usa CD Targeted Bispecific Antibody Products, Services and Solutions
7.7.4 Genentech Usa CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.7.5 Genentech Usa Recent Developments
7.8 Astella Pharma
7.8.1 Astella Pharma Profile
7.8.2 Astella Pharma Main Business
7.8.3 Astella Pharma CD Targeted Bispecific Antibody Products, Services and Solutions
7.8.4 Astella Pharma CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.8.5 Astella Pharma Recent Developments
7.9 Ben Kang Biopharmaceutical (Shenzhen)
7.9.1 Ben Kang Biopharmaceutical (Shenzhen) Profile
7.9.2 Ben Kang Biopharmaceutical (Shenzhen) Main Business
7.9.3 Ben Kang Biopharmaceutical (Shenzhen) CD Targeted Bispecific Antibody Products, Services and Solutions
7.9.4 Ben Kang Biopharmaceutical (Shenzhen) CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.9.5 Ben Kang Biopharmaceutical (Shenzhen) Recent Developments
7.10 Merus
7.10.1 Merus Profile
7.10.2 Merus Main Business
7.10.3 Merus CD Targeted Bispecific Antibody Products, Services and Solutions
7.10.4 Merus CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.10.5 Merus Recent Developments
7.11 Regeneron Pharmaceuticals
7.11.1 Regeneron Pharmaceuticals Profile
7.11.2 Regeneron Pharmaceuticals Main Business
7.11.3 Regeneron Pharmaceuticals CD Targeted Bispecific Antibody Products, Services and Solutions
7.11.4 Regeneron Pharmaceuticals CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.11.5 Regeneron Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 CD Targeted Bispecific Antibody Industrial Chain
8.2 CD Targeted Bispecific Antibody Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CD Targeted Bispecific Antibody Sales Model
8.5.2 Sales Channel
8.5.3 CD Targeted Bispecific Antibody Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

The global market for CD Targeted Bispecific Antibody was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for CD Targeted Bispecific Antibody was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CD Targeted Bispecific Antibody was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for CD Targeted Bispecific Antibody was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of CD Targeted Bispecific Antibody include Aptevo Therapeutics, Affimed Gmbh, Sutro Biopharma, Igm Biosciences, Xencor, Amgen, Genentech Usa, Astella Pharma and Ben Kang Biopharmaceutical (Shenzhen), etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for CD Targeted Bispecific Antibody, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CD Targeted Bispecific Antibody by region & country, by Type, and by Application.
The CD Targeted Bispecific Antibody market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD Targeted Bispecific Antibody.

Market Segmentation
By Company
Aptevo Therapeutics
Affimed Gmbh
Sutro Biopharma
Igm Biosciences
Xencor
Amgen
Genentech Usa
Astella Pharma
Ben Kang Biopharmaceutical (Shenzhen)
Merus
Regeneron Pharmaceuticals
Segment by Type:
CD3
CD20
CD40
Others
Segment by Application
Biotechnology
Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CD Targeted Bispecific Antibody manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CD Targeted Bispecific Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CD Targeted Bispecific Antibody in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 CD Targeted Bispecific Antibody Product Introduction
1.2 Global CD Targeted Bispecific Antibody Market Size Forecast
1.3 CD Targeted Bispecific Antibody Market Trends & Drivers
1.3.1 CD Targeted Bispecific Antibody Industry Trends
1.3.2 CD Targeted Bispecific Antibody Market Drivers & Opportunity
1.3.3 CD Targeted Bispecific Antibody Market Challenges
1.3.4 CD Targeted Bispecific Antibody Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CD Targeted Bispecific Antibody Players Revenue Ranking (2023)
2.2 Global CD Targeted Bispecific Antibody Revenue by Company (2019-2024)
2.3 Key Companies CD Targeted Bispecific Antibody Manufacturing Base Distribution and Headquarters
2.4 Key Companies CD Targeted Bispecific Antibody Product Offered
2.5 Key Companies Time to Begin Mass Production of CD Targeted Bispecific Antibody
2.6 CD Targeted Bispecific Antibody Market Competitive Analysis
2.6.1 CD Targeted Bispecific Antibody Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by CD Targeted Bispecific Antibody Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD Targeted Bispecific Antibody as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CD3
3.1.2 CD20
3.1.3 CD40
3.1.4 Others
3.2 Global CD Targeted Bispecific Antibody Sales Value by Type
3.2.1 Global CD Targeted Bispecific Antibody Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CD Targeted Bispecific Antibody Sales Value, by Type (2019-2030)
3.2.3 Global CD Targeted Bispecific Antibody Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Biotechnology
4.1.2 Laboratory
4.1.3 Others
4.2 Global CD Targeted Bispecific Antibody Sales Value by Application
4.2.1 Global CD Targeted Bispecific Antibody Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CD Targeted Bispecific Antibody Sales Value, by Application (2019-2030)
4.2.3 Global CD Targeted Bispecific Antibody Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global CD Targeted Bispecific Antibody Sales Value by Region
5.1.1 Global CD Targeted Bispecific Antibody Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CD Targeted Bispecific Antibody Sales Value by Region (2019-2024)
5.1.3 Global CD Targeted Bispecific Antibody Sales Value by Region (2025-2030)
5.1.4 Global CD Targeted Bispecific Antibody Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.2.2 North America CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.3.2 Europe CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.4.2 Asia Pacific CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.5.2 South America CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa CD Targeted Bispecific Antibody Sales Value, 2019-2030
5.6.2 Middle East & Africa CD Targeted Bispecific Antibody Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CD Targeted Bispecific Antibody Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CD Targeted Bispecific Antibody Sales Value
6.3 United States
6.3.1 United States CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.3.2 United States CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.4.2 Europe CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.5.2 China CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.5.3 China CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.6.2 Japan CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.7.2 South Korea CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.8.2 Southeast Asia CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CD Targeted Bispecific Antibody Sales Value, 2019-2030
6.9.2 India CD Targeted Bispecific Antibody Sales Value by Type (%), 2023 VS 2030
6.9.3 India CD Targeted Bispecific Antibody Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Aptevo Therapeutics
7.1.1 Aptevo Therapeutics Profile
7.1.2 Aptevo Therapeutics Main Business
7.1.3 Aptevo Therapeutics CD Targeted Bispecific Antibody Products, Services and Solutions
7.1.4 Aptevo Therapeutics CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.1.5 Aptevo Therapeutics Recent Developments
7.2 Affimed Gmbh
7.2.1 Affimed Gmbh Profile
7.2.2 Affimed Gmbh Main Business
7.2.3 Affimed Gmbh CD Targeted Bispecific Antibody Products, Services and Solutions
7.2.4 Affimed Gmbh CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.2.5 Affimed Gmbh Recent Developments
7.3 Sutro Biopharma
7.3.1 Sutro Biopharma Profile
7.3.2 Sutro Biopharma Main Business
7.3.3 Sutro Biopharma CD Targeted Bispecific Antibody Products, Services and Solutions
7.3.4 Sutro Biopharma CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.3.5 Igm Biosciences Recent Developments
7.4 Igm Biosciences
7.4.1 Igm Biosciences Profile
7.4.2 Igm Biosciences Main Business
7.4.3 Igm Biosciences CD Targeted Bispecific Antibody Products, Services and Solutions
7.4.4 Igm Biosciences CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.4.5 Igm Biosciences Recent Developments
7.5 Xencor
7.5.1 Xencor Profile
7.5.2 Xencor Main Business
7.5.3 Xencor CD Targeted Bispecific Antibody Products, Services and Solutions
7.5.4 Xencor CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.5.5 Xencor Recent Developments
7.6 Amgen
7.6.1 Amgen Profile
7.6.2 Amgen Main Business
7.6.3 Amgen CD Targeted Bispecific Antibody Products, Services and Solutions
7.6.4 Amgen CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.6.5 Amgen Recent Developments
7.7 Genentech Usa
7.7.1 Genentech Usa Profile
7.7.2 Genentech Usa Main Business
7.7.3 Genentech Usa CD Targeted Bispecific Antibody Products, Services and Solutions
7.7.4 Genentech Usa CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.7.5 Genentech Usa Recent Developments
7.8 Astella Pharma
7.8.1 Astella Pharma Profile
7.8.2 Astella Pharma Main Business
7.8.3 Astella Pharma CD Targeted Bispecific Antibody Products, Services and Solutions
7.8.4 Astella Pharma CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.8.5 Astella Pharma Recent Developments
7.9 Ben Kang Biopharmaceutical (Shenzhen)
7.9.1 Ben Kang Biopharmaceutical (Shenzhen) Profile
7.9.2 Ben Kang Biopharmaceutical (Shenzhen) Main Business
7.9.3 Ben Kang Biopharmaceutical (Shenzhen) CD Targeted Bispecific Antibody Products, Services and Solutions
7.9.4 Ben Kang Biopharmaceutical (Shenzhen) CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.9.5 Ben Kang Biopharmaceutical (Shenzhen) Recent Developments
7.10 Merus
7.10.1 Merus Profile
7.10.2 Merus Main Business
7.10.3 Merus CD Targeted Bispecific Antibody Products, Services and Solutions
7.10.4 Merus CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.10.5 Merus Recent Developments
7.11 Regeneron Pharmaceuticals
7.11.1 Regeneron Pharmaceuticals Profile
7.11.2 Regeneron Pharmaceuticals Main Business
7.11.3 Regeneron Pharmaceuticals CD Targeted Bispecific Antibody Products, Services and Solutions
7.11.4 Regeneron Pharmaceuticals CD Targeted Bispecific Antibody Revenue (US$ Million) & (2019-2024)
7.11.5 Regeneron Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 CD Targeted Bispecific Antibody Industrial Chain
8.2 CD Targeted Bispecific Antibody Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CD Targeted Bispecific Antibody Sales Model
8.5.2 Sales Channel
8.5.3 CD Targeted Bispecific Antibody Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/07/05 10:26

162.17 円

175.82 円

209.73 円

ページTOPに戻る